Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

Item

http://www.wikidata.org/entity/Q36798684

Q36798684

about

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical Trials Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Dapagliflozin combination therapy in type 2 diabetes mellitus.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

P2860

Q26782225-9F98D90B-B278-4523-ABA7-C5F5F31D1053 Q28553482-27C4D51B-340B-4535-839D-2F2110FAA368 Q30248634-AF24747C-4E68-4C79-B669-4E93E4DCB62C Q33166813-6A3E8E39-6480-460B-8D31-D1A9BE6AD8C0 Q36599869-E41BBC5C-F083-4CA0-9E66-9CF52DEB742B Q36712221-B6F7F53B-A630-473A-B087-950DFD404E6C Q37075620-C37E5721-23E2-4FD5-BC52-B35A4781B011 Q37310483-DD9BA149-4F3D-42AA-AAD6-67197239A0D0 Q38386194-212874E8-99CE-4E34-ACDF-076F413F5E80 Q38619164-890CFFAF-0361-4F44-AAC5-55E56211C5BE Q38634051-9837E3D3-4FBB-400A-9902-0D7FA9A76FEA Q38654762-ABA8A103-6054-41AC-A3BA-8C0BB798F640 Q38783203-E00077DA-4247-42A1-977B-90DEBC77ACDE Q38802437-07B7B21C-9468-4FA3-AAD1-496CFE120025 Q39023661-A68958A4-E184-4CD1-90CB-B40CD5870D3C Q39157526-025961C9-467B-43B0-8773-AB31E2E34777 Q39170860-94371D29-FB89-435B-ADAF-615625697ED6 Q39255188-A9F1132D-F9FB-4A81-A522-B8709AEEF4D7 Q39430445-658C18E3-5DA0-49DC-B916-6C6F54C48FA0 Q39865389-2EF2396D-1DC6-4C93-BD66-37AA2C041208 Q39892657-6E7ED3CE-308F-41CD-BA66-FD16EDD9C362 Q40266818-9D3FC4F7-3D18-440D-9034-C0C075F8C6A4 Q41678361-5D3EFC80-8D2F-4F5C-BAA2-574E3ED373BA Q42763621-02F5F3A7-A9CD-41FF-A29F-B87EC0825DF2 Q47137994-3DCD7A7A-EBFB-42D5-96D5-B9FE66B203FE Q47182784-8150183D-8C09-4838-B50C-C813FF3FC7FA Q47764756-75064DAB-D625-4FA5-8065-D89ACAD195AB Q48189020-709F036E-4A20-45E9-9BDD-C062DBD5BDBB Q51245889-5B53CBA0-BBD6-40A1-9986-743D98FA5B78 Q51293370-3186291C-28A4-402C-B004-DC761869D4AB Q52889769-4DF91834-93D7-4E7A-825E-3695594BF613 Q55210155-56A6900D-8AA2-4E14-B06E-381C4C8A2006

P2860

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

Item

http://www.wikidata.org/entity/Q36798684

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dapagliflozin's Effects on Gly ...... tudy With a 28-Week Extension.

@en

type

Item

label

Dapagliflozin's Effects on Gly ...... tudy With a 28-Week Extension.

@en

prefLabel

Dapagliflozin's Effects on Gly ...... tudy With a 28-Week Extension.

@en

P1476

Dapagliflozin's Effects on Gly ...... tudy With a 28-Week Extension.

@en

P2093

Ingrid Gause-Nilsson

http://www.w3.org/2001/XMLSchema#string

Jennifer Sugg

http://www.w3.org/2001/XMLSchema#string

Lawrence A Leiter

http://www.w3.org/2001/XMLSchema#string

Shamik J Parikh

http://www.w3.org/2001/XMLSchema#string

Tjerk W A de Bruin

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Standards of medical care in diabetes--2013

SGLT2 inhibitors in the treatment of type 2 diabetes.

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program.

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

P304

1218-1227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC14-0315

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William T. Cefalu

P577

2015-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25852208

http://www.w3.org/2001/XMLSchema#string

P921

placebo

type-2 diabetes

multicenter trial

P932

4831907

http://www.w3.org/2001/XMLSchema#string

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

about

P2860

P2860

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932